Science
RiboBridge: protein-conditioned de novo RNA binder structure design
arXiv:2610.30668v1 Announce Type: cross Abstract: Designing RNA molecules that bind to target protein structures requires generating both an RNA conformation and its bound complex geometry, without assuming a predefined binding…
- Published
- (4 days ago)
- Outlet
- arXiv q-bio.BM
- Section
- Science
- Length here
- Headline and 30-word snippet. The full article is at the source.
More from arXiv q-bio.BM and around the same time
Agent-guided epitope excision enables economical de novo binder designarXiv:2610.33195v1 Announce Type: new Abstract: De novo protein design campaigns remain bottlenecked by the inference compute time required to generate and rank candidates, limiting wider functional exploration. Here, we…Coder as Editor: Code-driven Interpretable Molecular EditingarXiv:2510.14455v2 Announce Type: replace-cross Abstract: Molecular design is a central task in drug discovery that requires precise structural reasoning and domain knowledge. While large language models (LLMs) have shown promise…MechGate: combining mechanism-derived measures of permeation and efflux to screen small molecule drugs targeting Escherichia coliarXiv:2610.33809v1 Announce Type: new Abstract: Most antibiotic molecules must cross the cell membrane and escape efflux pumps before hitting their targets. For de novo antibiotic design, very few of the in-silico-generated drug…mdRNAcat: A Molecular Dynamics RNA Catalog of REST2 Conformational EnsemblesarXiv:2610.35204v1 Announce Type: new Abstract: Learning molecular models of RNA requires simulation data that capture conformational variability and provide consistent physical training signals. Here, we introduce mdRNAcat, a…Computational De Novo Design of Miniprotein Candidate Neutralizers Targeting the IL-23 Cytokine Subunit p19arXiv:2610.32779v1 Announce Type: new Abstract: Interleukin-23 (IL-23) drives T-helper-17 inflammation underlying inflammatory bowel disease and psoriasis; anti-p19 antibodies are clinically effective but large, costly, and…Probe Before You Edit: Probing-Guided Molecular Optimization for LLM Agents in Structure-Based Drug DesignarXiv:2606.00555v3 Announce Type: replace-cross Abstract: Structure-based drug design increasingly employs LLM agents to iteratively refine ligands against a target pocket, yet a viable ligand must satisfy two often-conflicting…This page holds the headline and a short snippet as published by arXiv q-bio.BM, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
